Compare HYFM & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYFM | SXTP |
|---|---|---|
| Founded | 1977 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 3.6M |
| IPO Year | 2020 | 2023 |
| Metric | HYFM | SXTP |
|---|---|---|
| Price | $0.81 | $0.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.70 |
| AVG Volume (30 Days) | 251.7K | ★ 299.6K |
| Earning Date | 11-20-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.77 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,252,000.00 | $1,005,471.00 |
| Revenue This Year | $54.93 | N/A |
| Revenue Next Year | $5.31 | $70.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.49 |
| 52 Week Low | $0.50 | $0.34 |
| 52 Week High | $3.20 | $8.62 |
| Indicator | HYFM | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 33.12 |
| Support Level | $0.81 | $0.59 |
| Resistance Level | $1.04 | $1.63 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 57.89 | 10.03 |
Hydrofarm Holdings Group Inc is an independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture (CEA), including grow lights, climate control solutions, grow media, nutrients, and other products. Hydroponics involves growing plants in soilless media, often using artificial lighting in controlled indoor or greenhouse environments. Its products are used to cultivate cannabis, flowers, fruits, vegetables, grains, and herbs, enabling control over key factors such as temperature, humidity, light, nutrients, and pH. Its product portfolio spans lighting, grow media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies. The United States generates maximum revenue.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.